The practical recommendation is the same regardless of starting weight: follow the standard titration schedule, adjust based on tolerance, and let your response guide the maintenance dose
Cardiovascular benefits have been demonstrated in clinical trials for specific GLP-1 receptor agonists, with liraglutide, semaglutide, and dulaglutide showing reductions in major adverse cardiovascular events in patients with established cardiovascular disease or high cardiovascular risk
This is in line with a previous study that reported a median age at PBH diagnosis of 46 years and a longer median time to diagnosis of PBH, 40.6 months [39]
As coverage expands and evidence grows, expect oral GLP1 agents to take a more central role in both primary care and specialty settings
First, it provides objective evidence of treatment efficacy, helping you and your healthcare provider determine whether the medication is achieving therapeutic goals or whether dose adjustments are needed